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Abstract 
<Background: Critical illness and injury are known to alter the process of thermoregulation 
causing a change in temperature that will have an impact on coagulation and clinical outcome. 
This in-vitro preclinical study explores the relationship between temperature change and 
hemostasis using a recently validated rheological technique. In this study we aim to show that 
temperature change alone can cause a significant alteration in the microstructural properties of 
the clot. 
<Methods: The rheological technique measures the attainment of the Gel Point which provides 
three related biomarkers of clot quality; elasticity of the clot (G`GP), time to the gel point (TGP) 
and clot microstructure (df). Gel Point measurements were performed on whole blood samples 
from 136 healthy volunteers over a temperature range of 27-43oC. 
<Results: Across the whole temperature range from 27 to 43°C, we see a progressive 
shortening of TGP with corresponding increases in G`GP and df. We observed   significant 
correlations between df, G`GP and TGP across the whole temperature range (p<0.001). 
Furthermore when comparing the changes in df to the ‘normal’ at 37C (1.74 ± 0.035), we 
observe a significant reduction at temperatures equating to moderate hypothermia (≤32oC) 
(p=0.05). 
<Conclusions: This study shows that temperature change alone is sufficient to have an impact 
on the formation and properties of the clot. We found that significant changes were observed 
in df and TGP when temperatures fell into the moderate and severe hypothermic range.  
 Number of words: 232 
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IntroductionExtremes of body temperature occur in approximately 50% of patients admitted 
to the critical care unit and  contribute to morbidity and mortality.1,2 Changes in the progression 
of disease and its treatment can alternate between hypothermic or hyperthermic conditions, 
which result from a wide range of clinical complications.3 Where hypothermic states are often 
associated with hypocoagulable effects and hyperthermic states are associated with 
hypercoagulable conditions.4-9  However, clinically the isolated effect of temperature change 
on coagulation is difficult to ascertain  as it is often accompanied by other co-morbidities that 
may also alter coagulation. Previous studies have attempted to investigate the effect of 
temperature change on coagulation by using a variety of viscoelastic techniques.ref  These 
techniques include thromboelastography (TEG), rotational thromboelastometry (ROTEM) and 
free oscillation rheometry, and show that hypothermia impairs coagulation.8-10 In general the 
rate of coagulation and formation of the clot is increased, although the effect on the maximum 
clot strength is unclear. With some studies showing no change in the maximum clot strength, 
others showing significant changes at temperatures of 28°C[30],  and others showing 
significant changes at 33°C.ref .[27,30,31] 89 free oscillation 
 
Hyper and hypocoagulable changes in blood have been shown to affect the fibrin network 
which forms the basis of the clot microstructure is organized. 10-13 Clots formed under 
hypercoagulable conditions will have a denser more tightly packed microstructures which are 
more difficult to breakdown through lysis, when compared to a clot formed under 
hypocoagulable which would have a more open and loose network.ref  Furthermore, the 
microstructure of the clot determines its elastic properties and resistance to deformation.ref 
 
Commented [M1]: Old paper 
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Recent advances in the studies of viscoelastic changes in coagulation have led to the 
development of a novel rheological test for the analysis of clotting characteristics, including an 
assessment of clot microstructure.10,14-16 In contrast to standard coagulation assays, this 
technique uses unadulterated whole blood and accurately measures coagulation based on the 
attainment of a Gel Point.10,14 The rheological measurements at the Gel Point provides three 
important and related measurements; the elasticity of the clot (G`GP), time to the gel point (TGP) 
and an assessment of clot microstructure (df). In previous in vitro studies of hemodilution and 
anticoagulation we have shown that the measurement of the Gel Point provides improved 
predictors of changes in coagulation compared to conventional markers.refs 
 
The aim of this pre-clinical in vitro study is to determine whether temperature change alone 
causes alterations in coagulation and identify the exact temperature where these changes 
become significant, using the Gel Point measurements.  
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Methods 
The study was approved by the Wales Research Ethics Committee 6 with fully informed and 
written consent obtained from all subjects before enrolment. The inclusion criterion included 
male and female volunteers who were recruited from a known healthy database.  The exclusion 
criteria were 1) individuals with acute or chronic conditions known to effect coagulation, (i.e. 
malignancy, hepatic and/or renal dysfunction); 2) individuals taking anti-platelet or anti-
coagulation treatment; 3) individuals with a family history of bleeding or thromboembolic 
disorders; and 4) anyone under the age of 18.  
 
Blood Sampling 
Prior to blood sampling each healthy volunteer was assigned to one test temperature, ranging 
from 27ºC to 43ºC increasing in 1° increments (n=8 for each temperature). Blood samples were 
obtained from the antecubital vein via an 18 -gauge needle, the first 2mls of blood were 
discarded following which 20ml was collected in a plastic syringe. The blood sample were then 
immediately  divided into 2 aliquots. The first whole blood aliquot was transferred immediately 
to the AR-G2 (TA instruments, New Castle, DE, USA) rheometer for testing. The second 
sample was used for subsequent standard coagulation screening and full blood counts to ensure 
that each volunteer had a normal coagulation profile.  
 
Gel Point Measurements  
The Gel Point technique has been previously validated for use with blood.14 A more detailed 
description of the Gel Point technique can be sound in the online supplemental (S1). In the 
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present study 6.6 ml  of whole non-anticoagulated venous blood was immediately after 
bloodletting placed into a double-gap concentric cylinder geometry testing surface amounted 
on a TA Instruments AR-G2 (TA Instruments, New Castle, DE, USA) controlled-stress 
rheometer. The testing surfaces of the double-gap concentric cylinder geometry was set and 
controlled to one of the specified temperatures mentioned above. Immediately after loading 
measurements of viscoelastic properties of coagulating blood were taken and the formation of 
the Gel Point recorded, which identifies the transition of the blood from a visco-elastic liquid 
to a visco-elastic solid. The Gel Point provides three separate but related markers of 
coagulation; (i) the time taken to reach the Gel Point (the incipient clot formation time), TGP; 
(ii) the shear elastic modulus at the Gel Point, GGP, which is a measure of clot elasticity; and 
(iii) the fractal dimension of the clot, df, which is a quantification of the clot structure.  
Close temperature control was achieved in the AR-G2 rheometer via an integrated peltier 
concentric cylinder system. The PCC is valid for use between -10 to 150°C and is accurate to 
within 0.1°C. To ensure its accuracy the temperature of the PCC was checked by loading the 
testing surface with a fluid (normal saline), setting to the required temperature then immersing 
a thermocouple (P.I.8013, Portec type K theromometer, Wrestlingworth, UK) and recording 
the temperature. The process was repeated for all temperatures studied, in all cases the 
temperature reported by the PCC unit was within ±0.1°C of the temperature set on the AR-G2 
rheometer. The time taken for whole blood to reach the test temperatures after being loaded 
onto the testing surface (within 0.1°C) never exceeded 10 seconds.  
 
Computational Simulation 
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In conjunction with the Gel Point measurements we also provide a previously published 
computational simulation. This simulation will be used alongside the experimental data 
collected from the Gel Point measurements, to help illustrate how any changes in incipient clot 
microstructure (df) will relate to changes in the mass of the clot.17 This computational 
simulation will use the established relationship between incipient fibrin clots and there fractal 
properties, where the mass, M, is related to df by the following power law equation [M ≈ ɛdf, 
where ɛ is a length scale value in the range 100nm to 10μm].18  
 
Standard Coagulation Markers 
The second aliquot of blood (4.5 ml of the remaining blood) was immediately transferred to a 
siliconized glass Vacutainer (Becton-Dickinson, Plymouth, UK Ref: 367691) for routine 
coagulation studies, including Prothrombin Time (PT), activated Partial Thromboplastin Time 
(aPTT), and fibrinogen concentration measured using the  Clauss method.ref These were 
measured using a Sysmex CA1500 analyzer within 2 hours of collection. Fibrinogen 
concentration was verified against the 2nd International Fibrinogen Standard Version 4 (NIBSC 
code 96-612). All reagents were obtained from Siemens, (Frimley, UK). The analyzer was 
calibrated according to manufacturer’s instructions.  
 
Statistical Analysis 
Statistical analysis was performed using Minitab® version 16 software (Havertown, PA) and 
GRAPHPAD PRISM® version 6.0 (GraphPad software Inc., La Jolla, CA, USA). Data was 
confirmed as normally distributed using Anderson-Darling method and Tukey`s pairwise 
analysis used to determine when true differences arose. Pearson correlation was undertaken to 
Commented [CH6]: Reference Claus method. 
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explore associations between temperature, df, TGP and G`GP. Data was assumed to be significant 
when p<0.05 unless otherwise stated.  The primary aim was to establish at what temperature 
significant changes in df would occur compared to the value at 37°C. To determine the number 
of participants we would need in each of the temperatures we performed a power calculation. 
When temperature is decreased into the moderate or severe hypothermic range (below 33°C) 
we would expect a decrease in df or around  0.06, reductions similar to those seen in other in 
vitro studies and where the df at 37°C seen in a previous study was 1.73±0.035. ref Taking 
an  = 0.05 and a power of 0.90, we calculated that we would need an n of  8 for each 
temperature, giving a total of 136 participants. 
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Results  
Blood was obtained from 136 healthy volunteers. The standard coagulation measurements 
reported in Table 1 were normal for all subjects and were performed at 37°C. At 37ºC the value 
of df = 1.73 (±0.039) and TGP = 231(±55), were commensurate with those reported for healthy 
volunteers measured at 37°C in two previous studies.10,14 Figure 1 shows that increasing or 
decreasing temperature above or below 37°C results in incremental changes in the Gel Point 
measurements. Progressive increases in temperature from 27 to 43°C resulted in a progressive 
increase in both df and G`GP, showing significant positive correlations with temperature of ?? 
and ?? respectively (see Figure 1).  TGP was seen to decrease as temperature increased (??). We 
found that df significantly decreased from its baseline value (37ºC) (p<0.05) when temperatures 
reached 32°C (see Figure 1). A decrease in TGP occurs at 27°C (p=0.05). Significant 
correlations were found between TGP and df (r= -0.562, p<0.001) and between df and G`GP (r = 
0.719, p<0.001).  
 
The computational simulation (Figure 2a) shows that for values of df in the lower temperature 
range, large decreases in clot mass are observed. Figure 2b shows that a df of 1.65 
(corresponding to a temperature of 28°C) would produce a clot that contains approximately 
40% the mass from a clot formed with a df of 1.73 (37°C) (see Figure 2c). Figure 2a shows that 
the small incremental increases in df would require exponential increases in mass. Figure 2d 
shows that a df of 1.80 (some of the highest single values observed) would require a structure 
with 120%  additional mass compared to one formed at a df of 1.73. 
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Discussion  
This study shows that changes in temperature of the blood has a significant impact on the 
formation of the clot. We found that significant changes were observed in the Gel Point 
measurements of clot formation when temperatures fell into hypothermic range. Hypothermia 
is common in critical illness, trauma and surgery and has been linked with excessive bleeding, 
blood transfusion, and poor outcomes.1 In the literature it has been divided into mild (32° to 
35.9°C), moderate (28° to 32.9°C) and severe (less than 27.9°C) 25-27. Previous in vitro studies 
have shown that temperatures in the range 33° to 35.9°C cause a minimal effect on the 
enzymatic activity of coagulation factors6,7, however reduced platelet adhesion and aggregation 
is present. Where temperatures below a threshold of 36.4oC and 34oC have been shown to slow 
GPIIb/IIa and P-selectin activation respectively, both important in platelet adhesion.7,19  As 
temperature is reduced beyond 33°C, into the moderate and severe hypothermic ranges, a 
further inhibitory effect on platelet activity is observed,5,7 coupled with a progressive decrease 
in the enzymatic activity of coagulation factors, where at 25oC enzyme activity ranges from 0 
% (FVIII and FIX) to 5% (FII and FVII).,5,7,21  
 
In the present study we report a progressive decrease in df and G`GP with a prolongation of TGP 
as temperature is reduced below 37°C (see Figure 1). The progressive changes observed in df 
and TGP at temperatures below 37°C are indicative of a worsening hypocoagulable state, 
producing df and TGP values more commonly associated with anticoagulated or diluted 
blood.10,14 Whilst changes  are observed in the range of 33°C to 36°C, the change from the 
values at 37°C do not become significant until a temperature of 32°C is reached and only in 
the case of df (1.73±0.040 at 37°C to 1.67±0.037 at 32°C p<0.05). One advantage of this 
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rheological technique is that it includes the vital contribution of platelets and cellular 
components of coagulation, one major disadvantage of current routine coagulation laboratory 
tests. However, over the temperature range 33° to 35.9°C, the stated inhibitory effect on platelet 
adhesion does not seem sufficient to produce significant changes in the Gel Point parameters 
alone. When temperatures reach those synonymous with moderate hypothermia (below 33°C), 
the additional platelet and coagulation enzyme activity inhibition are likely to be the cause of 
this significant reduction in df. We only observe a significant change in TGP when the 
temperature falls to 27°C (??±?? at 37°C to ??±?? at 27°C p<0.05) and no significant change 
is observed in G`GP. This suggests that clot microstructure is more sensitive to the changes in 
temperature.  
 
Hyperthermic conditions have been associated with hypercoagulablity, where increases in 
temperature result in a net increase in thrombin generation.21 In the present study when 
temperature was increased above 37oC (up to 43oC) we observe no significant changes in df 
G`GP and TGP (Figure 1). These findings when compared to the changes in df observed in the 
hypothermic range, suggests that clot microstructure is more susceptible to reductions in 
temperature than increases. Across the whole range of temperatures studied (27-43°C) we 
record significant correlations between temperature and the three gel point parameters (df, TGP 
and G`GP). Where an increase in temperature has a profound effect on the formation and 
characteristics of the clot, creating faster forming, more compact clots with increased elasticity. 
Where, the significant correlations found between df & TGP and df & G`GP suggesting the 
structural organization of the clot (df) is related to the kinetics of clot formation (TGP) and its 
elastic properties (G`GP),  
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To better understand the impact of changes in df it is important to recognize what they represent 
in terms of the fibrin mass incorporated within the clot. To achieve this we use a previously 
published computational analysis that illustrates the non-linear relationship between df and clot 
mass at the incipient clot stage of development (see Figure 2). When temperature is reduced a 
progressive decrease in df is observed, Figure 2 reveals that a clot with df=1.67 (33°C) has 
approximately 60% of the mass of a clot for which df = 1.73 (37°C). This value is reduced 
further when considering the lowest temperature investigated in this study (27°C) which has a 
mean df of 1.62 and would contain approximately 40% mass. Small increases in df will result 
in an exponential increase in the mass of the network. A change from 1.73 to 1.80 requiring 
some 120% extra mass.   From a clinical perspective, these substantial changes in the clot mass 
are significant, given its role as a microstructural template for clot development.17 The 
consequences of increased mass will make the clot more difficult to lyse due to increased 
polymerized fibrin in a more tightly packed structure resulting in increases in clot elasticity. 
This is supported by the  positive significant correlation between df and G`GP herein.  This may 
be understood in terms of the viscoelasticity of cross-linked polymeric gel networks in which 
G` is a function of polymer chain length between cross links. For idealized networks with fixed 
cross links, increases in both G` and df will result from increased cross link density.22  
The major limitation of the study was not being able to perform Gel Point measures at all 17 
different temperatures for all volunteers. This was due to the test being performed using whole 
non-anticoaglated blood, where only a limited number of AR-G2 instruments were available 
and not wanting to bleed the volunteers multiple times.  As such blood from different healthy 
volunteers was used at each temperature interval. To limit any possible variations between the 
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groups all participants were drawn from a known healthy database and did not exceed the limits 
of the healthy range for df. The Gel Point measurements are taken at the initial or incipient 
stage of clot development and are not measures of the mature clot. This has the advantage of 
providing a very rapid measure of the clotting properties. Additionally we have shown 
previously how the incipient clot acts as a template of mature clot growthref and that df is 
significantly correlated with other viscoelastic measurements of the mature clot.ref   
 
This is the first study that quantifies how alterations in temperature result in significant changes 
in the quality of the clot. This study highlights the potential of the Gel Point technique as an 
improved measure of coagulation, furthermore we demonstrate the importance of performing 
coagulation analysis at the patient’s body temperature. Maintaining normothermia may be 
important, the results of this study would suggest that preventing moderate to severe 
hypothermia (<32oC) could be important. The Gel Point measurements have now been 
validated in models of anticoagulation, dilution and temperature.10,14 These studies identify that 
the Gel Point measurement can potentially be used in monitoring the pathophysiological 
progression, regression and treatment of an individual, to improve the management of critically 
ill patients with abnormal thermal conditions or undergoing surgery. The results of this in vitro 
study highlight the need for further clinical studies, such as studying the role of temperature in 
critical illness for example, sepsis and burns.  
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Table 1: The normal coagulation profile of the study participants with normal ranges for 
reference. 
Coagulation profile Result Normal range 
PT (sec) 10.4  ±  0.4 9 – 12.5 
APTT (sec) 25.7  ± 1.9 22.1 – 30.9 
Fibrinogen Clauss (g/l) 2.9  ±  0.5 1.5 – 4.2 
Haemaglobin (g/l) 149  ±  15 130 – 180 
Platelets (x109/l) 263  ±  58 150 – 400 
Haematocrit (vo/vol) 0.441  ±  0.039 0.40 – 0.52 
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Figure 1: Graphs of the changes in df (a), TGP (b) and G`GP (c) with progressive alterations 
in temperature. a) At lower temperatures a reduced value of df is observed, which represents 
a poorly formed, weak, porous clot. The reverse is seen at high temperatures, with a stronger, 
more densely formed clot produced. b) At lower temperatures a progressive prolongation of 
TGP is observed indicating a hypocoagulable response, conversely at higher temperatures a 
shortening of TGP is present indicating a hypercoagulable response. c) A progressive increase 
in G`GP is observed as temperature is increased, indicating a general increase in clot strength 
at higher temperatures. (*p<0.05 1-way ANOVA Tukey’s pairwise analysis). Dotted lines 
represent the mean and standard deviation at 37°C. 
 
Figure 2 – Computational simulation of df vs. mass: 2a) Graph showing the relationship 
between df and mass incorporated into the structure. Substantial increases in mass are required 
to generate small increments of df. The mass value on the y-axis is normalized for the healthy 
index value of df (=1.73). Figure 2 (b), (c) and (d): Illustrations of different incipient clot 
microstructures at particular values of df are provided (cross = 1.65, circle = 1.73 and square = 
1.80 respectively). The color of each node (unit sphere) within the fractal represents the local 
density of constituent nodes within a sphere of radii 5 units, the color ranges from green (1 
neighboring node) to red (20 neighboring nodes). 
 
